8-bromo-5-chloro-3-[(4-methylphenyl)sulfonyl]pyrrolo[2',3':4,5]pyrimido[6,1-b]quinazolin-7(3H)-one hydrochloride | 1116238-40-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 8-bromo-5-chloro-3-[(4-methylphenyl)sulfonyl]pyrrolo[2',3':4,5]pyrimido[6,1-b]quinazolin-7(3H)-one hydrochloride
• 英文别名: 4-Bromo-17-chloro-14-(4-methylphenyl)sulfonyl-1,9,14,16-tetrazatetracyclo[8.7.0.03,8.011,15]heptadeca-3(8),4,6,9,11(15),12,16-heptaen-2-one;hydron;chloride；4-bromo-17-chloro-14-(4-methylphenyl)sulfonyl-1,9,14,16-tetrazatetracyclo[8.7.0.03,8.011,15]heptadeca-3(8),4,6,9,11(15),12,16-heptaen-2-one;hydron;chloride
• CAS: 1116238-40-4
• 化学式: C₂₀H₁₂BrClN₄O₃S*ClH
• 分子量: 540.224
• InChiKey: ZNEAJAMJEIATOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.28
• 重原子数：
  31
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  92.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  8-bromo-5-chloro-3-[(4-methylphenyl)sulfonyl]pyrrolo[2',3':4,5]pyrimido[6,1-b]quinazolin-7(3H)-one hydrochloride 、 3,4,5-三甲氧基苯胺 以 四氢呋喃 为溶剂， 以73%的产率得到8-bromo-3-[(4-methylphenyl)sulfonyl]-5-{[3,4,5-tris(methyloxy)phenyl]amino}pyrrolo[2',3':4,5]pyrimido[6,1-b]quinazolin-7(3H)-one hydrochloride
  参考文献：
  名称：

  Reversible Carboxamide-Mediated Internal Activation at C(6) of 2-Chloro-4-anilino-1H-pyrrolo[2,3-d]pyrimidines

  摘要：

  A synthetic route to bisanilino-1H-pyrrolo[2,3-d]pyrimidines has been discovered, wherein the C(6)-chloride reactivity is necessarily enhanced via reversible acid-catalyzed internal activation of the pyrimidine ring by a C(1')-carboxamide moiety. Subsequent selective nucleophilic displacements at C(6) and C(1') constitute a one-pot tandem protocol for the rapid assembly of bisanilino-1H-pyrrolo[2,3-d]pyrimidines.

  DOI：

  10.1021/jo8020693
• 作为产物：
  描述：

  2-bromo-6-({2-chloro-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)benzoic acid 在 草酰氯 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 1.0h， 以90%的产率得到8-bromo-5-chloro-3-[(4-methylphenyl)sulfonyl]pyrrolo[2',3':4,5]pyrimido[6,1-b]quinazolin-7(3H)-one hydrochloride
  参考文献：
  名称：

  Reversible Carboxamide-Mediated Internal Activation at C(6) of 2-Chloro-4-anilino-1H-pyrrolo[2,3-d]pyrimidines

  摘要：

  A synthetic route to bisanilino-1H-pyrrolo[2,3-d]pyrimidines has been discovered, wherein the C(6)-chloride reactivity is necessarily enhanced via reversible acid-catalyzed internal activation of the pyrimidine ring by a C(1')-carboxamide moiety. Subsequent selective nucleophilic displacements at C(6) and C(1') constitute a one-pot tandem protocol for the rapid assembly of bisanilino-1H-pyrrolo[2,3-d]pyrimidines.

  DOI：

  10.1021/jo8020693

文献信息

• [EN] 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE 2-[(2-{PHÉNYLAMINO}-1H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]BENZAMIDE EN TANT QU'INHIBITEUR D'IGF-1R POUR LE TRAITEMENT DU CANCER
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009020990A1

  公开（公告）日：2009-02-12

  Novel pyrrolopyrimidines as shown in formula (I) and pharmaceutically acceptable derivatives thereof. The compounds are useful in the inhibition of IGF-1R.

  新型吡咯吡嘧啶如公式(I)所示，及其药用可接受的衍生物。这些化合物在抑制IGF-1R方面是有用的。
• 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer
  申请人：Chamberlain Stanley Dawes

  公开号：US20100204196A1

  公开（公告）日：2010-08-12

  Novel pyrrolopyrimidines as shown in formula (I): and pharmaceutically acceptable derivatives thereof. The compounds are useful in the inhibition of IGF-1R.

  式(I)所示的新型吡咯吡咪啉及其药学上可接受的衍生物。这些化合物在抑制IGF-1R方面是有用的。
• 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer
  申请人：GlaxoSmithKline LLC

  公开号：US07981903B2

  公开（公告）日：2011-07-19

  Novel pyrrolopyrimidines as shown in formula (I): and pharmaceutically acceptable derivatives thereof. The compounds are useful in the inhibition of IGF-1R.

  式(I)所示的新型吡咯吡嗪化合物及其药学上可接受的衍生物。这些化合物可用于抑制IGF-1R。
• 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D]PYRIMIDIN-4-YL) AMINO]BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：EP2188292B1

  公开（公告）日：2013-05-29
• US7981903B2
  申请人：——

  公开号：US7981903B2

  公开（公告）日：2011-07-19